TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01508195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin tablets
Description: Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR tablets
Description: Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin/metformin IR FDC tablets
Description: Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin/metformin IR FDC tablets
Description: Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin tablets
Description: Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR tablets
Description: Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
Study: NCT00324753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication
Description: Communication sheet

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of care
Description: Standard of care brochures
Study: NCT02257996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Systematic Brief Psychodynamic Psychotherapy
Description: Systematic Adaptative Diagnosis System will be applied in both groups at two different times: pre-treatment and post-treatment
Study: NCT00847184

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: Intubation using the standard MacIntosh blade

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: Intubation with the use of the Airtraq technique
Study: NCT04354298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improvisational Dance Class
Description: Hour long movement classes that meet weekly for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improvisational Dance Class
Description: Hour long movement classes that meet weekly for 12 weeks.
Study: NCT02180971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive CAG with EG test
Description: A positive finding for coronary angiography with an ergonovine provocation test is defined as transient, total, or sub-total occlusion (\>90% stenosis) with signs/symptoms of myocardial ischemia (chest pain and ischemic ECG change).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Negative CAG with EG test
Description: Negative test: less than 70% luminal narrowing, without chest pain or ST-segment changes after ergonovine coronary injection
Study: NCT01131416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gum chewing
Description: Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
Study: NCT02459769

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise for Cancer Patients
Description: a standardized, daily, 6 week, home-based, progressive exercise program

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise for Cancer Patients
Description: a standardized, daily, 6 week, home-based, progressive exercise program
Study: NCT02112136

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Collection
Description: Phenotype and Genotype Analysis, Biological Analysis
Study: NCT05869292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate implant loading
Description: Implants will be received immediately prosthetic restoration following surgical procedure.~For the provisional restoration, an open tray impression technique will be used. Plaster models with scan bodies will be digitized by the laboratory scanner (3Shape E1, 3Shape, Kopenhagen, Denmark), and the virtual design of provisional restoration will be performed with 3D designing software (Exocad-Matera 2.3, Exocad, Darmstadt, Germany). Provisional restorations will be then created using polymethyl methacrylate (PMMA) (Telio®CAD, Ivoclar Vivadent, Schaan, Lichtenstein) and were drilled from PMMA blocks using the 5-axis milling machine (Zenotec Select, Wieland, Pforzheim, Germany). Screw-retained abutments for the prosthetic bridge will be chosen according to implant angulation and surrounding soft tissue height.~At the end of the six-week healing period, definitive prosthetic restorations will be manufactured and delivered to the patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early implant loading
Description: Implants won't receive immediately prosthetic restoration following surgical procedure and will be left only healing caps.~At the end of the six-week healing period, definitive prosthetic restorations will be manufactured and delivered to the patients.
Study: NCT03042104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN 3 / SAPIEN 3 Ultra THV
Description: Patients will receive the SAPIEN 3 / SAPIEN 3 Ultra THV.
Study: NCT00962390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: 10mg S-equol 50mg S-equol, \& 150mg S-equol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: 10mg S-equol 50mg S-equol, \& 150mg S-equol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: 10mg S-equol 50mg S-equol, \& 150mg S-equol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03916887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Golf instruction
Description: Non-golfers instructed to golf over 10 weeks
Study: NCT04422990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lehfilcon A contact lenses
Description: Investigational silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A contact lenses
Description: Commercially available silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based contact lens cleaning and disinfecting solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based contact lens cleaning and disinfecting solution
Study: NCT01490814

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical isolation of the pulmonary veins
Description: Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical isolation of pulmonary veins
Description: Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
Study: NCT01089920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green tea
Description: Infusion (tea bags) from commercially available green tea

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green tea
Description: Infusion (tea bags) from commercially available green tea

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green tea
Description: Infusion (tea bags) from commercially available green tea

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Soluble coffee commercially available

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Soluble coffee commercially available

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Soluble coffee commercially available
Study: NCT03773198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Resonance through Cutaneous Stimulation
Description: The ERCS method involves listening to the body by applying fingers to the acupuncture skin points, developed according to the energy imbalance caused by illness, pain and emotional disorders.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaires
Description: Measurement of anxiety-trait and state-anxiety (Spielberger), pain ( numerical scale) and satisfaction (numerical satisfaction scale)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Measurement of anxiety-trait and state-anxiety (Spielberger), pain ( numerical scale) and satisfaction (numerical satisfaction scale)
Study: NCT03428074

Intervention type: PROCEDURE
Intervention: Surgeries
Description: Minimally invasive surgeries of Ivor-Lewis and Mckeown

Intervention type: PROCEDURE
Intervention: Surgeries
Description: Minimally invasive surgeries of Ivor-Lewis and Mckeown
Study: NCT00816309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acapella Physiotherapy
Description: twice daily- around 20 minutes
Study: NCT02749032

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mixed meal test
Description: Mixed meal test were performed in the morning after an overnight fast. The standardized mixed meal was composed of 2 eggs (100 g), 1 slice (50 g) of whole grain rye bread, 1 slice (50 g) of rye flour bread, 10 g of fat-reduced margarine, 20 g of boiled ham, and 25 g of diet jam, amounting to 450 kcal, 50 % carbohydrate, 20 % protein, and 30 % fat (based on calorie count). Patients were allowed to drink tea (black or fruit-based) or de-caffeinated coffee ad libitum.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mixed meal test
Description: Mixed meal test were performed in the morning after an overnight fast. The standardized mixed meal was composed of 2 eggs (100 g), 1 slice (50 g) of whole grain rye bread, 1 slice (50 g) of rye flour bread, 10 g of fat-reduced margarine, 20 g of boiled ham, and 25 g of diet jam, amounting to 450 kcal, 50 % carbohydrate, 20 % protein, and 30 % fat (based on calorie count). Patients were allowed to drink tea (black or fruit-based) or de-caffeinated coffee ad libitum.
Study: NCT00981110

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepore Self-adhesive absorbent dressing
Description: Standard dressing: medication performed as for frequency and duration according standard procedure
Study: NCT04913077

Intervention type: OTHER
Group type: OTHER
Intervention: removal of submucosal gastric tumor preferably by Full Thickness Resection Device (FTRD)
Description: FTRD (Ovesco company) in tumors up to 10 mm and predominantly intraluminal growth directly by sucking into the cap, at 10-20 mm and/or intramural/extramural growth by prior circumcision and lateral preparation, so that the lesions can be better pulled into the cap. The procedure depends on the endosonographic extent of the findings. The lesions are pulled into the cap with grippers and other instruments and, if necessary, with a snare and then resected with FTRD
Study: NCT03429114

Intervention type: OTHER
Intervention: Magnetic resonance imaging
Description: We will conduct MRI and fMRI brain scans to compare brain function between groups.

Intervention type: OTHER
Intervention: Magnetic resonance imaging
Description: We will conduct MRI and fMRI brain scans to compare brain function between groups.
Study: NCT02134496

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: assessment of motorfunction in PACU
Description: assessment of motorfunction in PACU after spinal anesthesia
Study: NCT03530917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7020531
Description: 4 SAD Cohorts with individual dosages of 40, 100, 140 and 170 mg hard capsules and 3 MAD Cohorts with dosages of 100 and 150mg hard capsules, will be administered orally as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7020531
Description: 4 SAD Cohorts with individual dosages of 40, 100, 140 and 170 mg hard capsules and 3 MAD Cohorts with dosages of 100 and 150mg hard capsules, will be administered orally as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7020531
Description: 4 SAD Cohorts with individual dosages of 40, 100, 140 and 170 mg hard capsules and 3 MAD Cohorts with dosages of 100 and 150mg hard capsules, will be administered orally as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7020531
Description: 4 SAD Cohorts with individual dosages of 40, 100, 140 and 170 mg hard capsules and 3 MAD Cohorts with dosages of 100 and 150mg hard capsules, will be administered orally as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7020531
Description: 4 SAD Cohorts with individual dosages of 40, 100, 140 and 170 mg hard capsules and 3 MAD Cohorts with dosages of 100 and 150mg hard capsules, will be administered orally as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7020531
Description: 4 SAD Cohorts with individual dosages of 40, 100, 140 and 170 mg hard capsules and 3 MAD Cohorts with dosages of 100 and 150mg hard capsules, will be administered orally as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo hard capsules will be administered orally as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo hard capsules will be administered orally as per the dosing schedules described above.
Study: NCT04202250

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CEMP (closed-ended multiport catheter) group
Description: After sterile preparation and large inguinal crease draping, with the US probe in a sterile sleeve or cover , we will proceed to hydrolocalization with 5-10 mL 5% dextrose in order to open the space between the femoral nerve and the superior part of the ilio-psoas muscle. The Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the closed-tip multiport catheter will be then inserted under control and its position assessed between the femoral nerve and the superior aspect of the ilio-psoas muscle. Some aliquots of 5% dextrose will inject to confirm correct dispersal of the solution along the femoral nerve. The catheter will be tunnelled subcutaneously.A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OESP (open-ended single port catheter) group
Description: After sterile preparation and large inguinal crease draping, with the US probe in a sterile sleeve or cover , we will proceed to hydrolocalization with 5-10 mL 5% dextrose in order to open the space between the femoral nerve and the superior part of the ilio-psoas muscle. The Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the open-ended catheter will be then inserted under control and its position assessed between the femoral nerve and the superior aspect of the ilio-psoas muscle. Some aliquots of 5% dextrose will inject to confirm correct dispersal of the solution along the femoral nerve. The catheter will be tunnelled subcutaneously. A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
Study: NCT03407404

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ketamine-Midazolam
Description: Continous intravenous sedation with 36mg of Midazolam and 900mg of Ketamine mixed in 50ml syringes as long as patient still requires sedation.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Morphine -Midazolam
Description: Continous intravenous sedation with 54mg of Morphine Sulphate and 36mg of midazolam mixed in 50ml syringes as long as participant still requires sedation.
Study: NCT01286454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine
Description: single dose of beads in capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine
Description: single dose of beads in capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine
Description: single dose of beads in capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine
Description: single dose of beads in capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine
Description: single dose of tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine
Description: single dose of beads in capsule
Study: NCT03965078

Intervention type: DRUG
Intervention: topical (eye drop) anti-inflammatories
Description: Initial treatment with topical anti-inflammatory eye drops at the discretion of the reviewing clinician

Intervention type: DRUG
Intervention: topical (eye drop) anti-inflammatories
Description: Initial treatment with topical anti-inflammatory eye drops at the discretion of the reviewing clinician
Study: NCT02827669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One Drop Experts Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One Drop Experts Program + Apple Watch
Study: NCT01350830

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior hernia repair
Description: Inguinal incision is made, external oblique divided and the cord is encircled after identifying ilioinguinal and iliohypogastric nerves. The sac is dissected and reduced, in case of direct hernia the posterior wall of inguinal canal is plicated with polypropylene suture; in presence of indirect hernia the sac is reduced and a stitch is passed in manner that the deep ring is snug about the cord. A pre-shaped mesh is positioned on the floor of the canal around the cord with the two tails overlapping laterally; the mesh is then anchored to the pubic tubercle. External oblique is reapproximated with the cord transposed in the subcutaneous space and skin is sutured.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transinguinal preperitoneal patch repair
Description: Through a 5-cm inguinal incision external oblique fascia is divided, cremasteric fibers are separated and the elements of the cord are skeletonized. Indirect or direct hernia is approached and through the hernia orifice, the sac is reduced, preperitoneal space is accessed and dissected to allow easily placement of the patch facilitated by the memory recoil ring. In case of indirect hernia the lateral part of patch is split and the two tails sutured around vas and gonadic vessels. Hernia orifice is closed with a polypropylene stitch through transversalis fascia and the mesh; external oblique is closed followed by skin approximation.
Study: NCT00872976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: One Week Initial Treatment for Cohort #1: Dasatinib - Tablets/Oral Solution, at assigned dose level, once daily (QD)
Study: NCT01872416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin Combined With ifosfamide
Description: Liposomal Doxorubicin Combined With ifosfamide Second-line Treatment in Small Cell Lung Cancer
Study: NCT00872976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Bendamustine + Dasatinib
Description: Dasatinib, Tablets/Oral Solution, Oral, 50 mg, then at 80 mg, at 80 mg, and at 100 mg, once daily (QD), at assigned ascending dose, for 28 day cycles for a maximum of six cycles~Bendamustine, injection, IV injection, 50 mg/m²/Day 1 and Day 2, then at 50 mg/m², at 70 mg/m², at 70 mg/m², at assigned ascending dose, once daily 30 minute IV infusion Day 1 and Day 2 for a maximum of six cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: One Week Initial Treatment for Cohort #2: Dasatinib - Tablets/Oral Solution, at 100 mg, once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Bendamustine + Dasatinib
Description: Dasatinib, Tablets/Oral Solution, Oral, at 100 mg, once daily (QD), for 28 day cycles for maximum of six cycles~Bendamustine, injection, IV injection, 100 mg/m²/Day 1 and Day 2, once daily 30 minute IV infusion Day 1 and Day 2 for maximum of six cycles
Study: NCT00935272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane®
Description: Restylane® injections in the lips

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Non-Treatment
Description: Non- Treatment
Study: NCT00017121

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study: NCT02281929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin+clavulanic acid at a daily dose of 3 gram / 375 mg in three daily doses of 1g/125mg, during 30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in three daily doses during 30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone at 40 mg/j in a single daily dose in the morning, during 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone at 40 mg/j in a single daily dose in the morning, during 30 days
Study: NCT03492554

Intervention type: OTHER
Group type: OTHER
Intervention: 1-Lead ECG
Description: All participants will record three single-lead ECGs

Intervention type: OTHER
Group type: OTHER
Intervention: 1-Lead ECG
Description: All participants will record three single-lead ECGs

Intervention type: DEVICE
Group type: OTHER
Intervention: 12-Lead ECG
Description: All participants will simultaneously record three 12-lead ECGs

Intervention type: DEVICE
Group type: OTHER
Intervention: 12-Lead ECG
Description: All participants will simultaneously record three 12-lead ECGs
Study: NCT01073241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transurethral ventral wall of urethra-preserving enucleation of prostate
Description: The patients' ventral wall of the prostate urethra was preserved and enucleation of prostate was performed for the left hyperplasia in the envelop.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transurethral prostatic resection
Description: The patients' prostate was resected with the conventional Nesbit TURP